Abstract PD9-02: Personalized ctDNA as a predictive biomarker in high-risk early stage breast cancer (EBC) treated with neoadjuvant chemotherapy (NAC) with or without pembrolizumab (P)
暂无分享，去创建一个
L. Esserman | S. Shchegrova | Hsin-Ta Wu | Minetta C. Liu | D. Yee | C. Yau | A. DeMichele | H. Sethi | D. Wolf | R. Nanda | L. Swigart | G. Hirst | R. Salari | B. Zimmermann | Angel A. Rodriguez | A. Aleshin | E. Kalashnikova | M. Magbanua | A. Delson | A. Tin | P. Billings | D. Renner | I. Investigators | L. Veer